AMCo moves debt into an amortising tranche, reducing loan size to £863m
Amdipharm Mercury, the UK generic pharmaceuticals company, has reduced the size of its £984m refinancing and recapitalisation loan and split the debt into amortising and bullet tranches.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: